Regeneron will temporarily extend physician payment terms for Eylea injection purchases for 150 days in response to the COVID-19 pandemic, the American Academy of Ophthalmology announced in a press release.
The new payment terms would extend the previous 100-day term, subject to distributor qualification. The company plans to implement the new terms by April 1 and have them apply to Eylea (aflibercept) retroactively to March 1, the release said.
“The COVID-19 pandemic is having a significant impact on patients and ophthalmologists. In some cases, it is limiting patient access to essential care,” Anne L. Coleman, MD, PhD, president of the AAO, said in the release. “We will continue to work with the health care community to find ways to help our patients and colleagues get through this difficult time. Regeneron’s prompt response to their needs will be extraordinarily beneficial.”
Ophthalmologists are asked to contact their specialty distributor with questions.